DENVER & TAMPA, Fla.--(BUSINESS WIRE)--May 31, 2023--
VieCure, a cancer care company with a market-leading artificial intelligence, informatics, and clinical decision support platform, announced today a new strategic collaboration with Clarified Precision Medicine which will make precision oncology more accessible for patients and community oncologists. In recent years there has been a large shift towards the use of patient-specific cancer treatment options that respond specifically to the molecular profile of the cancer (e.g., genomic data). These data points are complex, considerable, and difficult to access at the community oncology level based in part on the changing / updated tumor response data. This has highlighted a critical absence of medical guidance for both providers and payors and has motivated VieCure and Clarified Precision Medicine to work together to provide oncologists and their patients with clear, usable interpretations of any commercial comprehensive molecular profiling test along with a ranked list of treatment options which are reviewed by nationally recognized precision oncology experts. This partnership will also facilitate objective, third-party clinical review to assist a payor with prior authorization or an approval decision as part of the decision-making process for clinicians.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005225/en/
VieCure Platform (Photo: Business Wire)
VieCure will fully integrate the Clarified Precision Medicine Somatic and Germline Clinical Consultation process within its artificial intelligence platform and offer community oncologists streamlined access to Clarified’s nationally recognized test interpretation team. These professionals will function as elastic / on-demand supply for the clinical providers on the ground who are working tirelessly every day to help cancer patients and offer them with the best patient-specific options possible. Clarified Precision Medicine has also developed additional tools which help providers manage toxicities, optimize supportive care, and improve overall clinical efficiency.
The VieCure-Clarified partnership offers a precision oncology expert consideration, where elite, expert precision medicine guidance can be accessed while using the VieCure clinical decision support platform. “We are excited about embedding our expertise to further accelerate the adoption of precision oncology and help more patients and providers over the next several years,” said Dr. Howard McLeod, a nationally-recognized Precision Oncology expert.
VieCure will integrate the Clarified Medicine Precision testing tools within its platform and make the Clarified offering available to oncologists and clinical users later this year. Oncologists using the VieCure platform will be able to order their molecular test (e.g., next generation tumor sequencing) directly out of the VieCure platform and then obtain their precision medicine review within 48 hours following three easy steps:
- VieCure’s platform ingests discrete molecular test results for review and interpretation.
- Clarified Precision Medicine’s clinical experts will review the molecular test results.
- Upon receipt of the molecular test results, the clinical provider will receive an easy-to-understand report condensing the patient’s results into a ranked list of treatment options (including clinical trials) and suggestions about any additional testing, if necessary, directly within the VieCure platform. Furthermore, the provider also has the ability to connect with the Clarified Precision Medicine expert to discuss the results as needed.
VieCure will launch a pilot program at Alabama Cancer Care, granting early access to the ClarifiedSelect Report embedded in the VieCure platform. This is a tremendous step to improve access to next-generation cancer care for all and help ensure cancer patients live their best lives.
“VieCure and Clarified Precision Medicine, together, are further democratizing precision oncology and making it easier for community oncologists to offer the right care for the right patient every time,” said Dr. Fred Ashbury, Chief Scientific Officer at VieCure.
About VieCure
VieCure has developed a proprietary artificial intelligence informatics software platform in conjunction with a clinical inference engine and point-of-care decision support system in oncology. The VieCure™ platform combines the latest in clinical knowledge with patient data to assist clinicians in generating personalized treatment plans and better managing a patient’s treatment throughout diagnosis, cancer therapy, and ongoing follow-up care. For more information, please visit viecure.com and connect with VieCure on LinkedIn, Facebook, Twitter, Instagram, and YouTube.
About Clarified Precision Medicine
The Clarified Precision Medicine team is an elite collection of experienced practicing precision medicine clinicians. Clarified Precision Medicine is composed of nationally recognized talent in Medical Oncology, Oncology Pharmacy, Data Integration, and Molecular Pathology with over 85 years in the application of Precision Oncology. The Founders have built precision oncology programs in university, community, and integrated health systems. Clarified Precision Medicine offers expert clinical somatic and germline consultations through its ClarifiedSelect™ and OncoGuardian™ solutions.
View source version on businesswire.com:https://www.businesswire.com/news/home/20230531005225/en/
CONTACT: VieCure, Inc.
Hailey Hogue, Coordinator, Marketing and Social Media
hailey.hogue@viecure.com
Clarified Precision Medicine
Jody Simon, Chief Executive Officer
jody.simon@clarifiedmedicine.com
813.477.2700
KEYWORD: ALABAMA COLORADO FLORIDA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: SOFTWARE RESEARCH PROFESSIONAL SERVICES DATA MANAGEMENT ONCOLOGY TECHNOLOGY GENETICS ARTIFICIAL INTELLIGENCE HEALTH TECHNOLOGY DATA ANALYTICS SCIENCE BIOTECHNOLOGY HEALTH
SOURCE: VieCure
Copyright Business Wire 2023.
PUB: 05/31/2023 02:00 PM/DISC: 05/31/2023 02:00 PM
http://www.businesswire.com/news/home/20230531005225/en
